Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VBIOBullishCorporate Developmentsnews

High materiality8/10

Valion Bio secures Sheba-backed Entolimod trial, expanding oncology market potential

Jul 20, 2026, 1:31 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The collaboration with a world-class hospital and capital-efficient setup may accelerate data generation and attract partners, potentially improving VBIO's valuation. Prior biotech trial announcements with strong validation have driven near-term gains, especially when milestones occur in 2026-2027.

AI summary

What happened, with direct paths to the underlying reporting

Valion Bio announced Sheba Medical Center will evaluate Entolimod in cancer patients receiving high-dose irradiation, funding the trial and enabling a capital-efficient data path. The engagement creates a second clinical pathway beyond the FDA Animal Rule program for ARS and could unlock a multi-billion-dollar supportive oncology market if results prove protective and neutropenia-reducing. Key catalysts center on IRB approval and patient enrollment in 2026-2027, with topline data expected in 2027.

Sheba Medical Center selected Entolimod for cancer patients undergoing high-dose irradiation.
Trial up to 10 adults funded by Sheba, VBIO supplies the drug.
Expands Entolimod beyond ARS into neutropenia and supportive oncology.
Milestones through 2026-2027 could yield independent clinical data.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.